DaVita Inc. Q2 FY26 Results — Earnings Call Analysis
Published 30 May 2026 | Health Care Providers and Services | Market Cap: ₹12.7K Cr
- Treatment volume guidance raised from flat to 25-50 basis points growth for 2026, driven by better underlying performance and patient transfers from Fresenius clinic closures. - DaVita raised its 2026 adjusted operating income guidance to a range of $2.15 billion to $2.25 billion, driven primarily by higher treatment volume and lower patient care costs.
From DaVita Inc.'s Q2 FY26 earnings-call transcript · updated 30 May 2026.
Price
₹197.1
Market Cap
₹12.7K Cr
P/E Ratio
18.8
Revenue Rank
Margin Rank
How does DaVita Inc. rank in Health Care Providers and Services?
Compare DaVita Inc. against every Health Care Providers and Services company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 4- →Treatment volume guidance raised from flat to 25-50 basis points growth for 2026, driven by better underlying performance and patient transfers from Fresenius clinic closures.
- →Treatments per normalized day expected to grow 50-75 basis points in 2026.
- →Revenue per treatment (RPT) growth forecast remains 1% to 2% for the full year despite Q1 being about 4% higher due to timing effects.
- →Commercial mix is expected to decline over the year, potentially pressuring RPT.
- →Technology investments and AI deployment aim to improve operational efficiency and clinical outcomes, supporting sustainable volume and revenue growth.
- →Long-term focus on maintaining 3% to 7% operating income growth by balancing efficiency and clinical excellence.
📈 Profitability & Margins
Rank 3- →DaVita raised its 2026 adjusted operating income guidance to a range of $2.15 billion to $2.25 billion, driven primarily by higher treatment volume and lower patient care costs.
- →Adjusted EPS guidance was raised to a range of $14.10 to $15.20 per share, reflecting the improved operating income outlook.
- →The volume growth expectation was increased from flat to a range of 25 to 50 basis points growth, supported partly by patient transfers from Fresenius clinic closures.
- →Operating income growth is targeted to be sustained at 3% to 7% over time, emphasizing long-term efficiency and investment in clinicians.
- →Free cash flow guidance remains unchanged due to higher variability despite earnings growth.
- →Investments in technology and AI are expected to support sustainable outperformance and clinical and operational excellence in the long term.
🏗️ Capital Expenditure Plans
Yes- →DaVita is making targeted technology investments to expand their IT systems and digital infrastructure, empowering clinical teams and supporting future clinical and operational excellence.
- →Continued investment in AI solutions and data infrastructure modernization, including their proprietary EMR platform, to enhance clinical, operational, and business use cases.
- →Example given: deployment of ScheduleHub, a tool for optimizing patient and staffing schedules in real time, aiming to reduce administrative burden and improve teammate experience.
- →These tech investments are reflected in a 13% increase in G&A costs year-over-year due to sustained IT investment.
- →The approach to technology is long-term, focused on sustainability and outperformance rather than immediate timing of cost savings.
- →There's ongoing focus on optimizing total costs, including patient care, depreciation, amortization, and G&A, with a total cost CAGR of 2.6% over the past five years.
💰 Fundraising & Capital Structure
No information- →No specific mention of new fundraising through debt or equity in the call.
- →Debt expense for 2026 is expected to be about flat to last year, with quarterly debt expense similar to Q1 levels.
- →Share repurchases totaled 3 million shares in Q1 plus an additional 2 million shares post-quarter, including shares bought from Berkshire Hathaway under a repurchase agreement.
- →Leverage ratio at end of Q1 was 3.34x consolidated EBITDA, within target range of 3 to 3.5x.
- →The company appears focused on share repurchases rather than new equity issuance.
- →No indications of plans for new debt issuance; current debt expense guidance suggests stable debt levels.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Health Care Providers and Services this season
- BrightSpring Health Services, Inc. (Q2 FY26)
BrightSpring Health Services, Inc. Q2 FY26 quarterly results analysis. Pharmacy Solutions expected to see balanced sequential revenue and EBITDA growth througho
- Tenet Healthcare Corporation (Q2 FY26)
Tenet Healthcare Corporation Q2 FY26 quarterly results analysis. Hospital segment expects a 10% normalized year-over-year adjusted EBITDA growth in 2026, suppor
- Guardant Health, Inc. (Q2 FY26)
Guardant Health, Inc. Q2 FY26 quarterly results analysis. Sales team started this year with ~300 reps; incremental gross profit will be reinvested in expanding
- Quest Diagnostics Incorporated (Q2 FY26)
Quest Diagnostics Incorporated Q2 FY26 quarterly results analysis. Q1 2026 organic volume growth was strong at 10.8%, with total volume growth at 10.9%. Market
Frequently Asked Questions
What were DaVita Inc. Q2 FY26 results?
- Treatment volume guidance raised from flat to 25-50 basis points growth for 2026, driven by better underlying performance and patient transfers from Fresenius clinic closures. - DaVita raised its 2026 adjusted operating income guidance to a range of $2.15 billion to $2.25 billion, driven primarily by higher treatment volume and lower patient care costs.
What is DaVita Inc. share price analysis?
DaVita Inc. currently shows a neutral. The stock trades at a P/E of 18.8 with a market cap of $12,654. Investors should review the full earnings analysis for detailed insights.
Is DaVita Inc. planning capital expenditure?
- DaVita is making targeted technology investments to expand their IT systems and digital infrastructure, empowering clinical teams and supporting future clinical and operational excellence.
Keep DaVita Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.